Autologous Platelet‐Rich Plasma Drops for Evaporative Dry Eye Disease from Meibomian Gland Dysfunction: A Pilot Study
Open Access
- 1 July 2022
- journal article
- research article
- Published by Taylor & Francis Ltd in Clinical Ophthalmology
- Vol. ume 16, 2199-2208
- https://doi.org/10.2147/opth.s367807
Abstract
Purpose: To evaluate the effects of autologous platelet‐rich plasma (PRP) drops for evaporative dry eye (EDE) disease from meibomian gland dysfunction (MGD). Methods: This is a retrospective, consecutive case series of 20 eyes of 10 patients with EDE from MGD treated with PRP drops from November 2020 to November 2021 at a single outpatient clinic in Ontario, Canada. PRP drops were prepared from whole blood using a two-step centrifugation method. Patients were instructed to instill these drops six times daily for 4 weeks. The Canadian Dry Eye Assessment (CDEA) questionnaire score, patient subjective assessment (PSA) score, first and average non-invasive break-up times (f/a NIBUT), tear meniscus height (TMH), bulbar redness (BR), and meibograph grade (MG) were measured before and after the treatment course. Results: Significant improvements in dry eye symptoms and tear film parameters were observed. Dry eye symptoms significantly improved as per the CDEA (mean difference (MD) = − 5.45, 95% confidence interval (CI) = [− 7.9, − 3.1], p< 0.001) and PSA (MD = − 2.6, 95% CI = [− 3.9, − 1.2], p< 0.001). There were significant improvements in tear film parameters including fNIBUT (MD = 3.85s, 95% CI = [1.2, 6.8], p=0.006), aNIBUT (MD = − 6.81s, 95% CI = [5.7, 11.1], p< 0.001) and TMH (MD = 0.08, 95% CI = [0.003, 0.2], p=0.045). There was an improvement in conjunctival injection as measured by BR (MD = − 0.36, 95% CI = [− 0.4, − 0.15], p=0.373). Five eyes experienced a one-grade improvement in MG (p=0.453), and none experienced worsening in MG with treatment. No temporary or permanent adverse effects were noted. Conclusion: Four weeks of PRP therapy resulted in significant functional improvements in dry eye symptoms and tear film quality and quantity. Improvements in conjunctival injection and microstructural improvements in meibomian glands were also observed in some eyes. Overall, PRP is a promising treatment option for patients with EDE from MGD refractory to conventional treatments.Keywords
This publication has 44 references indexed in Scilit:
- Emerging treatment options for meibomian gland dysfunctionClinical Ophthalmology, 2013
- Topical Autologous Platelet-Rich Plasma Eyedrops for Acute Corneal Chemical InjuryCornea, 2012
- Autologous platelet lysate for treatment of refractory ocular GVHDBone Marrow Transplantation, 2012
- The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Management and Treatment of Meibomian Gland DysfunctionInvestigative Ophthalmology & Visual Science, 2011
- Understanding and Evaluating Platelet FunctionHematology, 2010
- Platelet-Rich Plasma: Where Are We Now and Where Are We Going?Sports Health: a Multidisciplinary Approach, 2010
- Use of Autologous Platelet-Rich Plasma in the Treatment of Dormant Corneal UlcersOphthalmology, 2007
- Symptomatic Dry Eye Treatment with Autologous Platelet-Rich PlasmaOphthalmic Research, 2007
- Use of Autologous Platelet Concentrate in Blepharoplasty SurgeryOphthalmic Plastic & Reconstructive Surgery, 2006
- Experimental Dry Eye Stimulates Production of Inflammatory Cytokines and MMP-9 and Activates MAPK Signaling Pathways on the Ocular SurfaceInvestigative Ophthalmology & Visual Science, 2004